Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
- Author:
Jun Young KIM
1
;
Dong Hyun SINN
;
Geum Youn GWAK
;
Gyu Seong CHOI
;
Aldosri Meshal SALEH
;
Jae Won JOH
;
Sung Ki CHO
;
Sung Wook SHIN
;
Keumhee Chough CARRIERE
;
Joong Hyun AHN
;
Yong Han PAIK
;
Moon Seok CHOI
;
Joon Hyeok LEE
;
Kwang Cheol KOH
;
Seung Woon PAIK
Author Information
- Publication Type:Original Article
- Keywords: Hepatocellular carcinoma; Intermediate stage; Transarterial chemoembolization; Resection; Survival
- MeSH: Adult; Aged; Carcinoma, Hepatocellular/mortality/pathology/*surgery; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms/mortality/pathology/*surgery; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Survival Rate; Treatment Outcome; alpha-Fetoproteins/analysis
- From:Clinical and Molecular Hepatology 2016;22(2):250-258
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality. METHODS: In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed. RESULTS: The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decision-tree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1-B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo' (2-4) nodules of intermediate size (5-10 cm) when the AFP levels was <400 ng/ml, or ‘oligo' (2-4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3). CONCLUSIONS: SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.
